BioSpace News Archive

Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development and commercialization of scientifically compelling assets from research universities and medical centers, announced today that its Scientific Co-founder, Jack A. Elias, MD, co-authored new findings in the peer-reviewed journal Immunity that detail the mechanisms behind the role of chitinase 3-like-1 (CHI3L1) in the growth of triple negative breast cancer.

Cerevance announced that chief executive officer, Craig Thompson, will participate in a fireside chat and host investor meetings at the RBC Capital Markets Healthcare Private Company Conference.

Eli Lilly and Company (NYSE: LLY) today announced results from the MONARCH 3 clinical trial, which will be presented in a late-breaking presentation during the 2023 San Antonio Breast Cancer Symposium (SABCS).

Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA) today announced that Health Canada has cleared Biomea’s Clinical Trial Application (CTA) to study BMF-219 in adults living with type 1 diabetes.

Applied DNA Sciences, Inc. today announced that it will release its fourth quarter and full year financial results 2023 ended September 30, 2023, on Thursday, December 7, 2023, after the market close.

ABK Biomedical, Inc. announces its Eye90 microspheres device has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA).

The Lung Cancer Research Foundation (LCRF) and the International Association for the Study of Lung Cancer (IASLC) today announced a new research partnership, titled IASLC - LCRF Team Science Research Grant on the Next Step in the Cure of Oncogene-Driven Lung Cancers.

BioInvent International today presents the first clinical data from a Phase 1/2a trial of its second FcyRIIB-blocking antibody BI-1607.

Exactech announced its subsidiary, BlueOrtho, has received 510(k) clearance from the Food and Drug Administration for ExactechGPS® Ankle, the world’s first surgical navigation system for total ankle arthroplasty (TAA).

Ceremorphic Life Sciences CEO Venkat Mattela delivered the keynote at today’s AI Driven Drug Discovery Summit in Boston MA, where he demonstrated the company’s new BioCompDiscoverX supercomputing platform.